Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Mizuho Securities Stick to Their Buy Rating for TCR2 Therapeutics Inc

Published 01/08/2021, 10:32 AM
Updated 01/08/2021, 10:32 AM


Mizuho Securities analyst Mara Goldstein maintained a Buy rating on TCR2 Therapeutics (NASDAQ:TCRR) Inc on Friday, setting a price target of $58, which is approximately 93.53% above the present share price of $29.97.

Goldstein expects TCR2 Therapeutics Inc to post earnings per share (EPS) of -$0.56 for the first quarter of 2021.

The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in TCR2 Therapeutics, with an average price target of $48.43.
The analysts price targets range from a high of $65 to a low of $37.

In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $0 and a net profit of -$17.19 million. The company's market cap is $1 billion.

According to TipRanks.com, Mizuho Securities analyst Mara Goldstein is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 18.6% and a 44.64% success rate.

TCR2 Therapeutics, Inc. is an immunotherapy company, which develops biological drugs and engineering T-cells for cancer therapy. The company offers cancer therapy, T-cell biology, Immunology and Molecular biology. It also engages in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded in May 2015 and is headquartered in Cambridge, MA.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.